Statements

COVID-19 Supply Situation | Sept. 22, 2022

We continue to monitor the global COVID-19 situation. The supply, manufacturing and distribution of Astellas products in the United States are not impacted, and patients will continue to be able to receive all approved US medicines, including our oncology and transplantation medicines, without interruption related to COVID-19. As the COVID-19 situation continues to evolve, Astellas remains focused on protecting our ability to manufacture and supply safe and effective medicines for patients who need them. Please direct any additional questions to our Medical Information line at 800-727-7003.

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Download Fact Sheet
Sustainability
Investors
Explore U.S. Products